Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)
Status:
Recruiting
Trial end date:
2024-02-28
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the efficacy, safety and tolerability of
Camrelizumab Combination With Nab-Paclitaxel and Epirubicin as Neoadjuvant Therapy in
Participants With Triple Negative Breast Cancer (TNBC)